HoldsUp

FoundMyFitness · 2023-12-27 · Rhonda Patrick (host), Peter Attia

Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging

135 research-tied claims examined: 13 contradicted 8 overstated 16 context 83 supported 15 unverified

8

Overstated

0:00:00Peter Attiaoverstatedmoderate

A little less than 50% of people with coronary artery disease experience sudden death as their first presenting symptom.

"A little less than 50% of people's first brush with a symptom of coronary artery disease is sudden death." (said at 0:00:00)

The claim overstates the proportion of coronary artery disease (CAD) patients whose initial presentation is sudden cardiac death. In long-term epidemiological cohorts such as the Framingham Heart Study, sudden cardiac death is well recognized as an initial clinical manifestation of coronary disease, but it represents the first presentation in approximately 15% to 20% of coronary heart disease cases (predominantly in men), not "a little less than 50%". The speaker's figure appears to conflate this rate with separate cardiovascular statistics, such as the fact that approximately 50% of all coronary heart disease deaths occur suddenly or out of hospital, or that roughly 50% of individuals who suffer sudden cardiac arrest had no prior recognized history of heart disease.

0:58:18Peter Attiaoverstatedhigh

Approximately 4% of individuals prescribed statins develop new-onset type 2 diabetes as a result of the medication.

"The other big side effect, the one that I probably think about the most, is insulin resistance. So, um, a very small set of subset of people, about 4% of people put on a statin, might go on to develop type 2 diabetes as a result of it." (said at 0:58:18)

Large-scale meta-analyses of randomized controlled trials demonstrate that statin therapy is associated with a modest increase in new-onset type 2 diabetes, but the proportion of patients who develop diabetes *as a result of* the medication (the drug-attributable excess risk) is approximately 0.4% (about 1 in 255 patients treated over 4 years), not 4%. The 4% figure corresponds roughly to the total cumulative incidence of diabetes observed in clinical trial cohorts (which occurred in approximately 4.5% to 4.8% of participants over 4 years), but the vast majority of these cases would have occurred regardless of statin therapy, predominantly among individuals with pre-existing prediabetes or elevated baseline HbA1c.

1:19:54Peter Attiaoverstatedlow

Research data indicate that when desmosterol levels are very low, the risk of Alzheimer's disease and all-cause dementia increases.

"There are enough data suggesting that if desmosterol levels are very low, the risk of AD does indeed go up, and the risk of dementia beyond AD goes up." (said at 1:19:54)

Observational and biomarker studies have found that plasma or serum desmosterol levels (and the desmosterol-to-cholesterol ratio, reflecting endogenous cholesterol synthesis) are significantly reduced in patients with Alzheimer's disease compared to cognitively normal controls, and correlate with cognitive decline and disease progression. However, the evidence is derived from relatively small cross-sectional and exploratory cohort studies examining desmosterol as a biomarker or disease correlate, rather than robust prospective epidemiological studies establishing that very low desmosterol levels causally or independently increase the future risk of Alzheimer's disease or all-cause dementia broadly.

1:47:07Peter Attiaoverstatedhigh

Sleep-depriving individuals down to 4 to 6 hours per night for several days causes up to a 50% reduction in glucose disposal measured by euglycemic clamp.

"So you do that test on somebody and then for a week sleep-deprive them down to 5 or 6, 4 hours a night—call it 4, 4 would be very dramatic—within days you'll see like a 50% reduction in their ability to dispose of glucose with no other difference: no dietary difference, no exercise difference." (said at 1:47:07)

Randomized controlled trials using the gold-standard hyperinsulinemic-euglycemic clamp demonstrate that restricting sleep to 4 to 5 hours per night for several days significantly impairs whole-body insulin sensitivity and glucose disposal under controlled diet and activity conditions. However, the magnitude of reduction is typically between 11% and 29%, making the claim of a 50% reduction an overstatement of the observed effect size.

1:58:15Peter Attiaoverstatedmoderate

The optimal interval duration for generating VO2 max adaptation is 3 to 8 minutes with a 1:1 work-to-recovery ratio.

"VO2 max sweet spot is 3 to 8 minutes with one-to-one rest to recovery, so three on, three off, three on, three off." (said at 1:58:15)

While long-interval high-intensity interval training (HIIT) using 3- to 8-minute bouts (such as the well-studied 4x4-minute protocol with ~3-minute recovery intervals) is an effective and common method for increasing VO2 max, evidence does not establish it as uniquely optimal over other interval configurations. Meta-analyses comparing interval training formats demonstrate that short-interval HIIT (e.g., 30–60-second work bouts) and sprint interval training (SIT) elicit robust and often comparable improvements in VO2 max, and network meta-analyses comparing protocol designs find no single interval duration or work-to-rest ratio structure to be clearly superior for maximizing time near VO2 max.

2:25:36Peter Attiaoverstatedhigh

Stage 1 breast cancer is a non-fatal disease, whereas stage 4 breast cancer is a uniformly fatal disease.

"If you catch this in a stage one, it's a non-fatal disease; a stage four disease is a uniformly fatal disease." (said at 2:25:36)

While stage I breast cancer has a very high 5-year relative survival rate and stage IV (metastatic) breast cancer has a poor long-term prognosis, describing stage I as a "non-fatal disease" and stage IV as "uniformly fatal" is an overstatement. Epidemiological studies and large clinical trial meta-analyses demonstrate that early-stage breast cancer carries a persistent risk of recurrence and mortality over extended follow-up. For instance, a meta-analysis of 88 clinical trials involving 62,923 women with ER-positive breast cancer found that even among patients with T1N0 disease (stage I) who completed 5 years of endocrine therapy, the risk of distant recurrence from years 5 to 20 was 13% (ranging from 10% to 17% depending on tumor grade), with a corresponding ongoing risk of breast cancer death. Conversely, while metastatic breast cancer remains largely incurable, modern therapies have substantially extended survival, and a meaningful fraction of stage IV patients survive past 5 years.

5:08:37Rhonda Patrick (host)overstatedlow

Studies demonstrate that serum 25-hydroxyvitamin D levels around 80 ng/mL are associated with lower all-cause mortality.

"going to 80, you know, like there's there's studies looking at 80 and it's still associated with lower all-cause mortality." (said at 5:08:37)

Observational cohort studies and meta-analyses consistently show that higher serum 25-hydroxyvitamin D [25(OH)D] concentrations compared to deficient levels (<10–20 ng/mL) are associated with lower all-cause mortality. However, the reduction in mortality typically plateaus around 30–40 ng/mL (75–100 nmol/L). While a small number of observational analyses have modeled associations extending into higher ranges, broad systematic reviews and individual participant meta-analyses find no additional mortality reduction at ~80 ng/mL (200 nmol/L) and frequently report U- or J-shaped curves where mortality risk levels off or rises at very high concentrations. Furthermore, randomized trials have not demonstrated longevity benefits from titrating vitamin D to such high serum levels.

3:35:23Peter Attiaoverstatedvery low

Elevated homocysteine impairs the clearance of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA).

"as homocysteine is elevated, it impairs the clearance of something called asymmetric and symmetric dimethylarginine." (said at 3:35:23)

The claim bundles two distinct methylated arginines and overstates in vitro mechanistic findings relative to in vivo evidence: 1. **ADMA Clearance**: Cell culture and in vitro studies show that elevated homocysteine can suppress the expression and activity of dimethylarginine dimethylaminohydrolase (DDAH), the primary enzyme responsible for degrading asymmetric dimethylarginine (ADMA). However, in vivo animal models of hyperhomocysteinemia show that tissue-specific downregulation of DDAH does not translate into elevated systemic ADMA levels or impaired ADMA clearance. 2. **SDMA Clearance**: Symmetric dimethylarginine (SDMA) is not a substrate for DDAH and is eliminated almost entirely via renal excretion. Homocysteine does not impair SDMA clearance.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.